Background and Aims Flawed ABC transporter functions may contribute to increased risk of drug-induced liver injury (DILI). We aimed to analyse the influence of genetic variations in ABC transporters on the risk of DILI development and clinical presentations in a large Spanish DILI cohort. Methods A total of ten polymorphisms in ABCB1 (1236T>C, 2677G>T,A, 3435T>C), ABCB4 (1954A>G) and ABCC2 (？1774G>del, ？1549A>G, ？24C>T, 1249G>A, 3972C>T and 4544G>A) were genotyped using Taqman 5′ allelic discrimination assays or sequencing in 141 Spanish DILI patients and 161 controls. The influence of specific genotypes, alleles and haplotypes on the risk of DILI development and clinical presentations was analysed. Results None of the individual polymorphisms or haplotypes was found to be associated with DILI development. Carriers homozygous for the ABCC2 ？1774del allele were however only found in DILI patients. Hence, this genotype could potentially be associated with increased risk, though its low frequency in our Spanish cohort prevented a final conclusion. Furthermore, carriers homozygous for the ABCC2 ？1774G/？1549A/？24T/1249G/3972T/4544G haplotype were found to have a higher propensity for total bilirubin elevations when developing DILI. Conclusions Our findings do not support a role for the analysed polymorphisms in the ABCB1, ABCB4 and ABCC2 transporter genes in DILI development in Spanish patients. The ABCC2 ？1774deldel genotype was however restricted to DILI cases and could potentially contribute to enhanced DILI susceptibility.
References
[1]
Andrade RJ, Robles M, Ulzurrun E, Lucena MI (2009) Drug-induced liver injury: insights from genetic studies. Pharmacogenomics 10: 1467–1487. doi: 10.2217/pgs.09.111
[2]
Morgan RE, Trauner M, van Staden CJ, Lee PH, Ramahandran B, et al. (2010) Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development. Toxicol Sci 118: 485–500. doi: 10.1093/toxsci/kfq269
[3]
Ulzurrun E, Stephens C, Crespo E, Ruiz-Cabello F, Ruiz-Nu？ez J, et al. (2013) Role of chemical structures and the 1331T>C bile salt export pump polymorphism in idiosyncratic drug-induced liver injury. Liver Int 33: 1378–1385. doi: 10.1111/liv.12193
[4]
Bodor M, Kelly EJ, Ho RJ (2005) Characterization of the human MDR1 gene. AAPS J 7: E1–E5. doi: 10.1208/aapsj070101
[5]
Wu CP, Hsieh CH, Wu YS (2011) The emergence of drug transporter-mediated multidrug resistance to cancer chemotherapy. Mol Pharm 8: 1996–2011. doi: 10.1021/mp200261n
[6]
Haas DW, Bartlett JA, Andersen JW, Sanne I, Wilkinson GR, et al. (2006) Pharmacogenetics of nevirapine-associated hepatotoxicity: an adult AIDS clinical trials group collaboration. Clin Infect Dis 43: 783–786. doi: 10.1086/507097
[7]
Ritchie MD, Haas DW, Motsinger AA, Donahue JP, Erdem H, et al. (2006) Drug transporter and metabolizing enzyme gene variants and nonnucleoside reverse-transcriptase inhibitor hepatotoxicity. Clin Infect Dis 43: 779–782. doi: 10.1086/507101
[8]
Ciccacci C, Borgiani P, Ceffa S, Sirianni E, Marazzi MC, et al. (2010) Nevirapine-induced hepatotoxicity and pharmacogenetics: a retrospective study in a population from Mozambique. Pharmacogenomics 11: 23–31. doi: 10.2217/pgs.09.142
[9]
Kamisako T, Gabazza EC, Ishihara T, Adachi Y (1999) Molecular aspects of organic compound transport across the plasma membrane of hepatocytes. J Gastroenterol Hepatol 14: 405–412. doi: 10.1046/j.1440-1746.1999.01886.x
[10]
Takikawa H (2002) Hepatobiliary transport of bile acids and organic anions. J Hepatobiliary Pancreat Surg 9: 443–447.
[11]
Choi JH, Ahn BM, Yi J, lee JH, Lee JH, et al. (2007) MRP2 haplotypes confer differential susceptibility to toxic liver injury. Pharmacogenet Genomics 17: 403–415. doi: 10.1097/01.fpc.0000236337.41799.b3
[12]
Daly AK, Aithal GP, Leathart JB, Swainsbury RA, Dang TS, et al. (2007) Genetic susceptibility to diclofenac-induced hepatotoxicity: contribution of UGT2B7, CYP2C8 and ABCC2 genotypes. Gastroenterology 132: 272–281. doi: 10.1053/j.gastro.2006.11.023
[13]
Oude Elferink RP, Paulusma CC (2007) Function and pathophysiological importance of ABCB4 (MDR3 P-glycoprotein). Pflugers Arch 453: 601–610. doi: 10.1007/s00424-006-0062-9
[14]
Stapelbroek JM, van Erpecum KJ, Klomp LW, Houwen RH (2010) Liver disease associated with canalicular transport defects: current and future therapies. J Hepatol 52: 258–271. doi: 10.1016/j.jhep.2009.11.012
[15]
Nicolaou M, Andress EJ, Zolnerciks JK, Dixon PH, Williamson C, et al. (2012) Canalicular ABC transporters and liver disease. J Pathol 226: 300–315. doi: 10.1002/path.3019
[16]
Aarnoudse AJ, Dieleman JP, Visser LE, Arp PP, van der Heiden IP, et al. (2008) Common ATP-binding cassette B1 variants are associated with increased digoxin serum concentration. Pharmacogenet Genomics 18: 299–305. doi: 10.1097/fpc.0b013e3282f70458
[17]
Kimchi-Sarfaty C, Oh JM, Kim IW, Sauna ZE, Calcagno AM, et al. (2007) A “silent” polymorphism in the MDR1 gene changes substrate specificity. Science 315: 525–528. doi: 10.1126/science.1135308
[18]
Lang T, Haberl M, Jung D, Drescher A, Schlagenhaufer R, et al. (2006) Genetic variability, haplotype structures, and ethnic diversity of hepatic transporters MDR3 (ABCB4) and bile salt export pump (ABCB11). Drug Metab Dispos 34: 1582–1599. doi: 10.1124/dmd.105.008854
[19]
Aithal GP, Watkins PB, Andrade RJ, Larrey D, Molokhia M, et al. (2011) Case definition and phenotype standardization in drug-induced liver injury. Cin Pharmacol 89: 806–815.
[20]
Benichou C (1990) Criteria of drug-induced liver disorders. Report of an international consensus meeting. J Hepatol 11: 272–276.
[21]
Andrade RJ, Lucena MI, Fernández MC, Pelaez G, Pachkoria K, et al. (2005) Drug-induced liver injury: an analysis of 461 incidences submitted to the Spanish registry over a 10-year period. Gastroenterology 129: 512–521. doi: 10.1016/j.gastro.2005.05.006
[22]
Pachkoria K, Lucena MI, Ruiz-Cabello F, Crespo E, Cabello MR, et al. (2007) Genetic polymorphisms of CYP2C9 and CYP2C19 are not related to drug-induced idiosyncratic liver injury (DILI). Br J Pharmacol 150: 808–815. doi: 10.1038/sj.bjp.0707122
[23]
Livak KJ (2003) SNP genotyping by the 5′-nuclease reaction. Methods Mol Biol 212: 129–147. doi: 10.1385/1-59259-327-5:129
[24]
Sai K, Saito Y, Itoda M, Fukushima-Uesaka H, Nishimaki-Mogami T, et al. (2008) Genetic variations and haplotypes of ABCC2 encoding MRP2 in a Japanese population. Drug Metab Pharmacokinet 23: 139–147. doi: 10.2133/dmpk.23.139
[25]
Urban TJ, Shen Y, Stolz A, Chalasani N, Fontana RJ, et al. (2012) Limited contribution of common genetic variants to risk for liver injury due to a variety of drugs. Pharmacogenet Genomics 22: 784–795. doi: 10.1097/fpc.0b013e3283589a76
[26]
Kim SH, Kim SH, Lee JH, Lee BH, Kim YS, et al. (2012) Polymorphisms in drug transporter genes (ABCB1, SLCO1B1 and ABCC2) and hepatitis induced by antituberculosis drugs. Tuberculosis 92: 100–104. doi: 10.1016/j.tube.2011.09.007
[27]
Laechelt S, Turrini E, Ruehmkorf A, Siegmund W, Cascorbi I, et al. (2011) Impact of ABCC2 haplotypes on transcriptional and posttranscriptional gene regulation and function. Pharmacogenomics J 11: 25–34. doi: 10.1038/tpj.2010.20
[28]
Meier Y, Pauli-Magnus C, Zanger UM, Klein K, Schaeffeler E, et al. (2006) Interindividual variability of canaclicular ATP-binding-cassette (ABC)-transporter expression in human liver. Hepatology 44: 62–74. doi: 10.1002/hep.21214
[29]
Hayes DDH, Flanagan JU, Jowsey IR (2005) Glutathioe transferases. Annu Rev Pharmacol Toxicol 45: 51–88. doi: 10.1146/annurev.pharmtox.45.120403.095857
[30]
Lee YM, Cui Y, K？nig J, Risch A, J？ger B, et al. (2004) Identification and functional characterization of the natural variant MRP3-Arg1297His of human multidrug resistance protein 3 (MRP3/ABCC3). Pharmacogenetics 14: 213–223. doi: 10.1097/00008571-200404000-00001
[31]
Shoda J, Kano M, Oda K, Kamiya J, Nimura Y, et al. (2001) The expression levels of plasma membrane transporters in the cholestatic liver of patients undergoing biliary drainage and their association with the impairment of biliary secretory function. Am J Gastroenterol 96: 3368–3378.
[32]
Jeannesson E, Albertini L, Siest G, Gomes AM, Ribeiro V, et al. (2007) Determination of ABCB1 polymorphisms and haplotypes frequencies in a French population. Fundam Clin Pharmacol 21: 411–418. doi: 10.1111/j.1472-8206.2007.00507.x
[33]
Hodges LM, Markova SM, Chinn LW, Gow JM, Kroetz DL, et al. (2011) Very important pharmacogene summary: ABCB1 (MDR1, P-glycoprotein). Pharmacogenet Genomics 21: 152–161. doi: 10.1097/fpc.0b013e3283385a1c
[34]
Leschziner G, Zabaneh D, Pirmohamed M, Owen A, Rogers J, et al. (2006) Exon sequencing and high resolution haplotype analysis of ABC transporter genes implicated in drug resistance. Pharmacogenet Genomics 16: 439–450. doi: 10.1097/01.fpc.0000197467.21964.67
